Thus, GSTM3TV2 could upregulate the expression of LAT2, OLR1 through competitively sponging let-7 to enhance gemcitabine resistance of PC, which suggested that GSTM3TV2/let-7/LAT2, OLR1 axis might act as a potential biomarker and therapeutic target for PC (63). This evidence concerns the gene OLR1 and pachyonychia congenita.